KJX839
Sponsors
Novartis Pharma AG, Novartis Pharmaceuticals
Conditions
Heterozygous Familial HypercholesterolemiaHypercholesterolaemiahomozygous familial hypercholesterolemia
Phase 3
Two part (double-blind inclisiran versus placebo [Year 1] followed by open-label inclisiran [Year 2]) randomized multicenter study to evaluate safety, tolerability and efficacy of inclisiran in children (2 to less than 12 years) with homozygous familial hypercholesterolemia and elevated LDL-cholesterol (ORION-19)
RecruitingCTIS2024-514595-41-00
Start: 2025-08-05Target: 6Updated: 2025-10-27
Two part (double-blind inclisiran versus placebo [Year 1] followed by open-label inclisiran [Year 2]]) randomized multicenter study to evaluate safety, tolerability and efficacy of inclisiran in children (6 to less than 12 years) with heterozygous familial hypercholesterolemia and elevated LDL-cholesterol (ORION-20)
RecruitingCTIS2024-514594-21-00
Start: 2025-03-13Target: 36Updated: 2025-09-01